Financials
Financial year 2025
HistoGeneX Holding from Antwerpen, company number BE0643686060, closed financial year 2025 with a result of € 24,715 after tax. Compared with financial year 2024, the result moved from € 117,553 to € 24,715. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 9, 2026.
€ 65.9 million
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 24,715
▼ 79% vs 2024
Profit after tax over the fiscal year.
€ 174,385
▲ 5% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 8.4 million.
People and assets in 2025
€ 16
▼ 97% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 437,607
▲ 145% vs 2024
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 162 days on average.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Profit after taxes | € 132,155 | € 125,889 | € 117,553 | € 24,715 | ▼ 79% |
| Equity | € 65,588,451 | € 65,714,339 | € 65,831,892 | € 65,856,608 | |
| Total debts | € 268,850 | € 235,271 | € 262,893 | € 521,878 | ▲ 99% |
| Cash | € 181,843 | € 177,987 | € 166,299 | € 174,385 | ▲ 5% |
| Retained profit | € 8,106,065 | € 8,231,953 | € 8,349,506 | € 8,374,221 | |
| Balance sheet total | € 65,857,301 | € 65,949,611 | € 66,094,786 | € 66,378,486 |
Key figures of HistoGeneX Holding, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to HistoGeneX Holding?
What happened at HistoGeneX Holding in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Elliot Miller stepped down as director. NBB
- Joshua Schultz stepped down as director. NBB
- Hendriks Consulting Company NV stepped down as director. NBB
- New annual accounts for financial year 2025: profit of € 24,715 (▼ 79% vs 2024). Source: NBB ↗
- Maurice Tenney III stepped down as director. NBB
- Kockx Consulting NV stepped down as director. NBB
- Elliot Miller became a director. NBB
- Anthony L. Mattacchione stepped down as director. NBB
In short
From € 132,155 profit in 2022 to € 24,715 profit in 2025.
Best year ever: 2022, with € 132,155 profit.
Pays suppliers within 162 days on average.
A new publication or filing at HistoGeneX Holding? We notify you, reason included.
Follow HistoGeneX HoldingDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
The stake of Arsenal IO Belgium comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
HistoGeneX HoldingThe shares are held by Arsenal IO Belgium (100%). It owns 83.3% of CELLCARTA NV itself.
Directors
According to the 2025 annual accounts
since 2023 · until 2026
since 2025 · until 2031
since 2019 · until 2025
Managing director · represented by Mark Kockx
Also active at: BATYO, CellCarta, PATHOMATION, Arsenal IO Belgium
since 2021 · until 2026
since 2022 · until 2025
since 2025 · until 2030
Hendriks Consulting Company NV
Managing director · represented by Dirk Hendriks
Also active at: CellCarta, Arsenal IO Belgium
since 2021 · until 2027
Shareholders
100%
Participations
83.3%
Establishments
Establishment units
Physical locations of this company
Sint-Bavostraat 78
2610 Antwerpen
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Website
Technologies
Hosting & Email
Email provider
Microsoft 365
Hosting
DIGITALOCEAN-ASN - DigitalOcean, LLC, US
Domain
Domain
cellcarta.com
Registered
2020-07-09
Registrar
GoDaddy.com, LLC
Expires
2026-07-09
Website info
Features
Security
Details
- Company number
- 0643.686.060
- VAT number
- BE 0643.686.060
- Registered office
- Sint-Bavostraat 78, 2610 Antwerpen
- Names & denominations
- HistoGeneX Holding
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 27 November 2015
- Peppol
- Active · Active since 14 Oct 2025
- Contact
- cellcarta.com
- Activities · NACE
Activiteiten van holdings
Holdings
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies
Overige zakelijke dienstverlening, neg
Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering